.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Cantor Fitzgerald
Julphar
Baxter
McKesson
Citi
US Army
Fish and Richardson
Colorcon
Deloitte

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,609,701

« Back to Dashboard

Which drugs does patent 8,609,701 protect, and when does it expire?


Patent 8,609,701 protects ESBRIET and is included in two NDAs.

This patent has fifty-three patent family members in thirty-five countries.

Summary for Patent: 8,609,701

Title:Pirfenidone treatment for patients with atypical liver function
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Inventor(s): Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:13/128,569
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genentech IncESBRIETpirfenidoneCAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► SubscribeCONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,609,701

PCT Information
PCT FiledNovember 09, 2009PCT Application Number:PCT/US2009/063702
PCT Publication Date:May 14, 2010PCT Publication Number: WO2010/054294

Non-Orange Book Patents for Patent: 8,609,701

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,566,729Modifying pirfenidone treatment for patients with atypical liver function► Subscribe
8,592,462Pirfenidone treatment for patients with atypical liver function► Subscribe
7,635,707Pirfenidone treatment for patients with atypical liver function► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,609,701

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
San MarinoT201500088► Subscribe
San MarinoT201100030► Subscribe
Slovenia2343070► Subscribe
Slovenia2191831► Subscribe
Serbia53721► Subscribe
Serbia51787► Subscribe
Portugal2343070► Subscribe
Portugal2191831► Subscribe
Peru06832011► Subscribe
Malaysia159353► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Medtronic
Mallinckrodt
Johnson and Johnson
Novartis
UBS
Deloitte
Cantor Fitzgerald
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot